Commodities & logistics Management
Main Strategic Objective
Maintain timely availability of safe and quality malaria commodities and supplies at the delivery points
Strategic Approach
- Promote partnership to ensure malaria commodities are available in all service delivery points in the right amount and when needed
- Promote partnership to ensure that all malaria commodities used at service delivery points are quality assured
- Promote partnership to ensure that all malaria commodities used at service delivery points are safe
Procurement and Supply Management
Strategic Approach
Promote partnership to ensure malaria commodities are available in all service delivery points in the right amount and when needed
Procurement Service Delivery Mechanisms
- Carry out annual quantification and gap analysis for all malaria commodities and supplies
- Properly conduct procurement of malaria commodities and supplies by promoting conducive partnership
- Enhance supply chain of medicines, diagnostics, insecticide treated materials, insecticides and larvicides, from point of entry/supplier to service delivery point.
- Enhance logistic management of medicines, diagnostics and other malaria commodities within the health care facilities including dispensing
Quality Control and Quality Assurance
Promote partnership to ensure that all malaria commodities used at service delivery points are quality assured
Commodities Quality Assurance Service Delivery Mechanisms
- To strengthen commodities quality check for commodities for vector control and case management
- Post Market surveillance for antimalarial medicines and malaria testing devices
- Post Market surveillance for vector control commodities, LLIN, insecticides and larvicides
Commodities Safety
Strategic Approach
Promote partnership to ensure that all malaria commodities used at service delivery points are safe
Commodities Safety Service Delivery Mechanisms
- Facilitate the relevant regulatory authorities (TMDA), to conduct passive pharmacovigilance for malaria medicine.
- Facilitate the relevant regulatory authorities (NIMR and TPRI), to conduct continuous evaluation of use practices and re–evaluation of potentially adverse effects to people and the environment